Evotec SE (EVO)

Evotec Appoints Rui Wang as Head of Global In Silico and AIJune 2, 2026 1:45 AM
ACCESS NewswireHAMBURG, DE / ACCESS Newswire / June 2, 2026 / Evotec SE (NASDAQ:EVO)(Frankfurt Prime Standard:EVT) today announced the appointment of Rui Wang as Executive Vice President, Head of Global In Silico and AI. Mr. Wang brings to Evotec more than 20 years of experience supporting global pharma and biotech organizations to embed scalable data, analytics & AI across R&D, drug development, manufacturing and supply chain functions. In his role, Mr. Wang will spearhead the integration of computational science and data-driven decision-making across the R&D operation, with the goal of creating enterprise-scale solutions that ensure AI and in silico science become key pillars of the Evotec commercial value proposition.Dr. Christian Wojczewski, Chief Executive Officer of Evotec, said:"Rui will play a key role in our ongoing effort to make Evotec's drug discovery and development enterprise a powerful engine of innovation, integration and operational efficiency. Advanced computational tools are essential to enhancing the value of both our business segments - Drug Discovery and Preclinical Development as well as Just - Evotec Biologics. These tools are not a separate entity but are embedded in everything we do to discover and develop new therapies."Mr. Wang most recently served as Head of Data, Analytics and AI at AstraZeneca, where he has held roles of increasing responsibility for more than a decade. Prior to that he held positions at European Molecular Biology Laboratory's European Bioinformatics Institute and at Tangram Therapeutics (formerly e-therapeutics). He holds M.Sc. degrees in Bioinformatics from the University of Manchester and in System Design for Internet Applications from Newcastle University.Rui Wang, Evotec's incoming Head of Global In Silico and AI, added:"The companies that will lead in AI-enabled drug discovery are those that learn from the right data, generated against the right biological questions, at scale. Evotec is uniquely positioned at the intersection of discovery, data and proprietary platforms. Our focus is to translate this position into a durable scientific advantage by concentrating on the capabilities where we can truly differentiate - scaling them with depth and rigor."About Evotec SEEvotec is a life science company that is pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies, we accelerate the journey from concept to cure - faster, smarter, and with greater precision. Our expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling. With flexible partnering models tailored to our customers' needs, we work with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders. Our offerings range from standalone services to fully integrated R&D programs and long-term strategic partnerships, combining scientific excellence with operational agility. Through Just - Evotec Biologics, we redefine biologics development and manufacturing to improve accessibility and affordability. With a strong portfolio of over 100 proprietary R&D assets, most of them being co-owned, we focus on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology, and immunology. Evotec's global team of more than 4,500 experts operates from sites in Europe and the U.S., offering complementary technologies and services as synergistic centers of excellence. Learn more at www.evotec.com and follow us on LinkedIn and X/Twitter @Evotec.Forward-looking statementsThis announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec's expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.Investor Relations and Media ContactDr. Sarah Fakih
EVP Head of Global Communications & Investor Relations
Sarah.Fakih@evotec.comSOURCE: Evotec SEView the original press release on ACCESS NewswireOriginal: Evotec Appoints Rui Wang as Head of Global In Silico and AI

Evotec SE Successfully Placed €116.1 Million Convertible BondsMay 12, 2026 5:15 PM
ACCESS NewswireNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR IN ANY OTHER JURISDICTION IN WHICH, OR TO PERSONS IN ANY JURISDICTION TO WHOM, SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW.HAMBURG, GERMANY / ACCESS Newswire / May 12, 2026 / Evotec SE (the "Company" or "Evotec") (NASDAQ:EVO)(Frankfurt Prime Standard:EVT) placed today senior unsecured convertible bonds due 2033, convertible into new and/or existing no-par value ordinary bearer shares of the Company (the "Shares"), in an aggregate principal amount of €116.1 million (the "Bonds"). The pre-emption rights of the shareholders were excluded.The Bonds will have a maturity of seven years with an investor put right after five years and will be issued at par in a denomination of €100,000 each. The Bonds will bear interest at a rate of 2.625% per annum payable semi-annually in arrear. The Bonds will be repaid at maturity at their accreted redemption amount of 110% of the principal amount (the "Accreted Redemption Amount"), implying a yield to maturity of 3.882%. The initial conversion price of €6.5313 corresponds to a conversion premium of 37.5% above the share reference price of €4.75, which is the share price of the Evotec Share determined in the Concurrent Delta Placement (as defined below). In light of the Accreted Redemption Amount, the effective conversion price of the Bonds is approx. €7.1844 at maturity.Settlement is expected to take place on or around 21 May 2026. The inclusion of the Bonds in the open market segment (Freiverkehr) of the Frankfurt Stock Exchange is intended. Evotec is subject to a lock-up period ending 90 days following the settlement date of the offering, subject to certain exemptions.The Company intends to use the net proceeds to support the cash out requirements of Project Horizon, its transformation program aimed to strengthen the Company's operating model and enable sustained long term value creation.In addition, a simultaneous placement of existing shares of the Company has been conducted (the "Concurrent Delta Placement") on behalf of certain buyers of the Bonds who wished to sell such shares in short sales to hedge the market risk of an investment in the Bonds at a placement price determined by way of an accelerated bookbuilding process. The Company will not receive any proceeds from this simultaneous offering of existing shares.BNP PARIBAS and Goldman Sachs Bank Europe SE acted as Joint Global Coordinators and, together with HSBC Continental Europe and Morgan Stanley, as Joint Bookrunners.About Evotec SEEvotec is a life science company that is pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies, we accelerate the journey from concept to cure - faster, smarter, and with greater precision. Our expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling. With flexible partnering models tailored to our customers' needs, we work with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders. Our offerings range from standalone services to fully integrated R&D programs and long-term strategic partnerships, combining scientific excellence with operational agility. Through Just - Evotec Biologics, we redefine biologics development and manufacturing to improve accessibility and affordability. With a strong portfolio of over 100 proprietary R&D assets, most of them being co-owned, we focus on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology, and immunology. Evotec's global team of more than 4,500 experts operates from sites in Europe and the U.S., offering complementary technologies and services as synergistic centers of excellence. Learn more at www.evotec.com and follow us on LinkedIn and X/Twitter @Evotec.Important note:This announcement and the information contained herein is restricted and may not be published, distributed or released, directly or indirectly, in the United States of America (including its territories and possessions), Australia, Canada, Japan, South Africa or any other jurisdiction where such publication, distribution or release would be unlawful. The publication, distribution or release of this announcement may be restricted by law in certain jurisdictions and persons who are in possession of this document or other information referred to herein should inform themselves about and observe any such restrictions. Further, this announcement is for information purposes only and is not an offer of, or a solicitation of an offer to purchase, sell or subscribe for, securities in any jurisdiction. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction.This announcement does not constitute a recommendation or advice concerning the placement of, or invitation to submit any offer to purchase, sell or subscribe for, any securities. Investors should consult a professional advisor as to the suitability of the placement of, or invitation to submit any offer to purchase, sell or subscribe for, any securities for the person concerned.This release does not constitute an offer of securities for sale in the United States of America (the "U.S."). Any securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or the laws of any state of the U.S., and may not be offered or sold in the U.S. absent registration or an exemption from registration under the Securities Act.Subject to certain exceptions, the securities referred to herein may not be offered or sold in or into the U.S., Australia, Canada, Japan, South Africa or to, or for the account or benefit of, any national, resident or citizen of Australia or Japan.MiFID II and UK MiFIR professionals/ECPs-only/No EU PRIIPs KID or CCI Regulations disclosure document - Manufacturer target market (MiFID II and UK MiFIR product governance) is eligible counterparties and professional clients only (all distribution channels). No EU PRIIPs key information document (KID) or CCI Regulations disclosure document has been prepared as not available to retail investors in the EEA or the UK.Investor Relations and Media ContactDr. Sarah Fakih
EVP Head of Global Communications & Investor Relations
Sarah.Fakih@evotec.comSOURCE: Evotec SEView the original press release on ACCESS NewswireOriginal: Evotec SE Successfully Placed €116.1 Million Convertible Bonds

Evotec Announces Nomination of First Preclinical Development Candidate in Dermatology Collaboration with AlmirallMay 4, 2026 1:50 AM
ACCESS NewswireJoint Evotec-Almirall team advances small molecule program to preclinical development significantly outperforming standard industry timelinesCollaboration leverages Evotec's end-to-end integrated AI/ML-driven R&D capabilities and Almirall's dermatology expertise HAMBURG, DE / ACCESS Newswire / May 4, 2026 / Evotec SE (NASDAQ:EVO)(Frankfurt Prime Standard:EVT) today announced the nomination of a small molecule preclinical development candidate (PDC) from its multi-target drug discovery alliance in medical dermatology with Almirall S.A. The program is aimed at developing novel treatments for immune-mediated inflammatory skin diseases with high unmet medical need.The nomination marks an important achievement for the collaboration, with the joint team progressing from initial leads to PDC within just two years. This accelerated timeline compares favorably to the typical industry benchmark for similar small molecule programs and highlights Evotec's ability to deliver high-quality candidates both rapidly and efficiently.The program leverages Evotec's fully integrated, AI/ML-enhanced discovery and preclinical development platforms including medicinal chemistry, DMPK, in vitro biology and development expertise within a seamless, data-driven workflow. Close coordination between discovery and development teams supported fast iteration cycles and consistent decision-making, ultimately leading to the identification of a high-quality preclinical candidate within an accelerated timeline.The alliance brings together Evotec's end-to-end discovery and preclinical development capabilities with Almirall's strong expertise and commitment to advancing medical dermatology. Almirall focuses on developing innovative therapies for patients living with skin diseases and on addressing areas of high unmet need in dermatology, particularly in immune-mediated dermatological conditions.Evotec will continue to support the program toward IND submission through its INDiGO platform, an integrated, accelerated IND-enabling platform designed to ensure a smooth transition from discovery to clinical readiness.Dr. Cord Dohrmann, Chief Scientific Officer of Evotec, said:"This program's speed and quality demonstrate the ability of our integrated, AI/ML-enabled discovery and preclinical development platforms to produce high-value candidates for clinical evaluation. Reaching a preclinical development candidate in such a short time validates our approach to data-driven, end-to-end drug discovery and exemplifies what can be achieved when scientific excellence is paired with a highly collaborative partnership such as our work with the dermatology expert Almirall. We are proud of the work accomplished by our teams and look forward to progressing this promising program toward the clinic."About the Evotec - Almirall collaborationEvotec entered into a collaboration with Almirall, a global biopharmaceutical company dedicated to medical dermatology, in May 2022. The collaboration targets the discovery and development of novel therapeutics for severe skin diseases, including a range of immune-mediated inflammatory conditions.The agreement included an undisclosed upfront payment to Evotec as well as research payments and success-based milestones of potentially up to €230 million per program and royalties on net sales in the high single-digit percentage range.About Evotec SEEvotec is a life science company that is pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies, we accelerate the journey from concept to cure - faster, smarter, and with greater precision. Our expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling. With flexible partnering models tailored to our customers' needs, we work with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders. Our offerings range from standalone services to fully integrated R&D programs and long-term strategic partnerships, combining scientific excellence with operational agility. Through Just - Evotec Biologics, we redefine biologics development and manufacturing to improve accessibility and affordability. With a strong portfolio of over 100 proprietary R&D assets, most of them being co-owned, we focus on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology, and immunology. Evotec's global team of more than 4,500 experts operates from sites in Europe and the U.S., offering complementary technologies and services as synergistic centers of excellence. Learn more at www.evotec.com and follow us on LinkedIn and X/Twitter @Evotec.Forward-looking statementsThis announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec's expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.Investor Relations and Media ContactDr. Sarah Fakih
EVP Head of Global Communications & Investor Relations
Sarah.Fakih@evotec.comSOURCE: Evotec SEView the original press release on ACCESS NewswireOriginal: Evotec Announces Nomination of First Preclinical Development Candidate in Dermatology Collaboration with Almirall

Evotec Receives Grants to Advance Tuberculosis TreatmentApril 30, 2026 3:20 AM
ACCESS NewswireGrants support discovery and development of novel drug candidates and evaluation and prioritization of advanced drug regimens for clinical testingNew funding from the Gates Foundation extends Evotec's commitment to create more effective tuberculosis treatment regimens HAMBURG, GERMANY / ACCESS Newswire / April 30, 2026 / Evotec SE (NASDAQ:EVO)(Frankfurt Prime Standard:EVT) today announced that it has received two grants from the Gates Foundation for drug discovery and translation in tuberculosis (TB), following four earlier TB grants from the foundation, amounting to $4.9 million over 25 months and $5 million over 24 months. The new funding underscores Evotec's commitment to translating innovative science into impactful therapies addressing high-priority public health threats.The grant programs will expand the pipeline of novel TB drug candidates and advance the most promising combinations toward clinical evaluation, reducing development risk and accelerating progress toward a universal, shorter, safer and simpler TB drug regimen.Although most TB patients can be cured with existing antibiotics, treatments are long, complex and difficult to complete, especially for drug-resistant forms of the disease leading to treatment failures. The new grants will enable Evotec to apply its state-of-the-art translational platforms, including AI-enabled drug discovery and translational evaluation, to discover and prioritize novel therapies that address these critical challenges.The first grant supports Evotec's discovery efforts to advance a portfolio of novel small molecules with the potential to treat all TB patients. By combining its advanced AI-enabled drug discovery platform with deep TB drug discovery expertise, Evotec aims to accelerate time to candidate selection and increase the likelihood of success, ultimately contributing to the development of improved treatment options.The second grant enables the nonclinical characterization of next-generation TB drug combinations proposed for late-stage clinical trials, including those with potential for delivery as Long Acting Injectables. Long Acting Injectables represent a potentially transformative innovation in TB therapy. Using its cutting-edge translational platforms, Evotec will generate data on pharmacokinetics, efficacy and resistance potential to inform optimal development pathways and de-risk progression to clinical testing.Dr. Cord Dohrmann, Chief Scientific Officer of Evotec, said:"We are grateful for the foundation's continued support. Effective TB drug development requires both a robust pipeline of novel candidates and rigorous translational evaluation to identify the combinations most likely to succeed in the clinic. These grants empower us to leverage our integrated AI-driven discovery and translational platforms to identify and advance the most promising candidates and combinations."About TuberculosisTuberculosis (TB) is an airborne infectious disease caused by Mycobacterium tuberculosis bacteria that primarily affects the lungs but can also impact other organs. Although curable with appropriate antibiotic regimens, the disease continues to impose a substantial global health burden, with an estimated 10.7 million new cases and 1.23 million deaths in 2024. Persistent challenges such as drug resistance and complex, burdensome treatment regimens highlight the need for improved diagnostics, shorter and safer therapies, and sustained investment in innovation.Evotec has a strong presence in TB drug discovery and translational science and is an active participant in leading global collaborations across the philanthropic, non-profit and private sectors, including the TB Drug Accelerator (TBDA), ERA4TB, and the PAN-TB collaboration. Through these partnerships, Evotec contributes to the accelerated discovery and development of novel TB drugs and treatment regimens aimed at improving outcomes for patients worldwide.About Evotec SEEvotec is a life science company that is pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies, we accelerate the journey from concept to cure - faster, smarter, and with greater precision. Our expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling. With flexible partnering models tailored to our customers' needs, we work with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders. Our offerings range from standalone services to fully integrated R&D programs and long-term strategic partnerships, combining scientific excellence with operational agility. Through Just - Evotec Biologics, we redefine biologics development and manufacturing to improve accessibility and affordability. With a strong portfolio of over 100 proprietary R&D assets, most of them being co-owned, we focus on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology, and immunology. Evotec's global team of more than 4,500 experts operates from sites in Europe and the U.S., offering complementary technologies and services as synergistic centers of excellence. Learn more at www.evotec.com and follow us on LinkedIn and X/Twitter @Evotec.Forward-looking statementsThis announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec's expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.Investor Relations and Media ContactDr. Sarah Fakih
EVP Head of Global Communications & Investor Relations
Sarah.Fakih@evotec.comSOURCE: Evotec SE
View the original press release on ACCESS NewswireOriginal: Evotec Receives Grants to Advance Tuberculosis Treatment

Evotec Announces New Nomination to Board of DirectorsApril 29, 2026 4:45 PM
ACCESS NewswireNomination of Dr. Wolfgang Hofmann as independent Supervisory Board member to further strengthen oversight and governance capabilitiesConclusion of cooperation agreement with MAK Capital following constructive discussions, reflecting Evotec's commitment to open shareholder dialogueAnnual General Meeting to vote on the appointments of Supervisory Board members and proposed expansion of Supervisory Board, supporting effective oversight and long-term value creation HAMBURG, GERMANY / ACCESS Newswire / April 29, 2026 / Evotec SE (NASDAQ:EVO)(Frankfurt:EVT) today announced the nomination of Dr. Wolfgang Hofmann for election as an independent member of the Supervisory Board at the company's upcoming Annual General Meeting (AGM) to be held on June 11, 2026. The AGM agenda also includes the previously announced nomination of Dieter Weinand as Chairman of the Supervisory Board, as well as a proposal to increase the size of the Supervisory Board from six to seven members.Following constructive discussions, Evotec has entered into a cooperation agreement with MAK Capital Fund LP ("MAK Capital"), a key shareholder of the company. Under the terms of the agreement MAK Capital has agreed to customary voting and cooperation commitments among other provisions.Prof. Dr. Iris Löw-Friedrich, Chairwoman of Evotec's Supervisory Board, said:"We are pleased to nominate Wolfgang for election at the upcoming AGM. His appointment would contribute oversight and governance capabilities through additional industry, scientific and governance expertise, complementing our existing Board structure as we continue to implement our transformation plans to grow shareholder value. The agreement reached, reflects Evotec's commitment to constructive shareholder engagement, supporting the long-term success of the Company."Michael A. Kaufman, Chief Executive Officer of MAK Capital, said:"We appreciate the constructive dialogue and welcome Wolfgang's nomination to the Supervisory Board. We look forward to continuing our collaboration with the Supervisory Board and Management Board to support Evotec's ongoing transformation."About Evotec SEEvotec is a life science company that is pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies, we accelerate the journey from concept to cure - faster, smarter, and with greater precision. Our expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling. With flexible partnering models tailored to our customers' needs, we work with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders. Our offerings range from standalone services to fully integrated R&D programs and long-term strategic partnerships, combining scientific excellence with operational agility. Through Just - Evotec Biologics, we redefine biologics development and manufacturing to improve accessibility and affordability. With a strong portfolio of over 100 proprietary R&D assets, most of them being co-owned, we focus on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology, and immunology. Evotec's global team of more than 4,500 experts operates from sites in Europe and the U.S., offering complementary technologies and services as synergistic centers of excellence. Learn more at www.evotec.com and follow us on LinkedIn and X/Twitter @Evotec.Forward-looking statementsThis announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec's expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.Investor Relations and Media ContactDr. Sarah Fakih
EVP Head of Global Communications & Investor Relations
Sarah.Fakih@evotec.comSOURCE: Evotec SEView the original press release on ACCESS NewswireOriginal: Evotec Announces New Nomination to Board of Directors

Evotec SE to Announce First Quarter 2026 Results on May 6, 2026April 29, 2026 1:50 AM
ACCESS NewswireHAMBURG, DE / ACCESS Newswire / April 29, 2026 / Evotec SE (NASDAQ:EVO; Frankfurt Prime Standard: EVT) will hold a webcast and conference call to announce its financial results for the first quarter 2026 and provide a business update on Wednesday, May 6, 2026. The conference call will be held in English.Webcast detailsDate: Wednesday, May 6, 2026Time: 2.00 pm CEST (12.00 pm GMT, 8.00 am EDT)To join the audio webcast and to access the presentation slides, please register via this link.The on-demand version of the webcast will be available on our website: www.evotec.com.Conference call detailsTo join the conference call, please pre-register via this link. You will then receive a confirmation email with dedicated dial-in details such as telephone number, access code and PIN to access the call.A simultaneous slide presentation for participants dialing in via phone is available under this link.About Evotec SEEvotec is a life science company that is pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies, we accelerate the journey from concept to cure - faster, smarter, and with greater precision. Our expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling. With flexible partnering models tailored to our customers' needs, we work with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders. Our offerings range from standalone services to fully integrated R&D programs and long-term strategic partnerships, combining scientific excellence with operational agility. Through Just - Evotec Biologics, we redefine biologics development and manufacturing to improve accessibility and affordability. With a strong portfolio of over 100 proprietary R&D assets, most of them being co-owned, we focus on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology, and immunology. Evotec's global team of more than 4,500 experts operates from sites in Europe and the U.S., offering complementary technologies and services as synergistic centers of excellence. Learn more at www.evotec.com and follow us on LinkedIn and X/Twitter @Evotec.Forward-looking statementsThis announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec's expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.Investor Relations and Media ContactDr. Sarah Fakih
EVP Head of Global Communications & Investor Relations
Sarah.Fakih@evotec.comSOURCE: Evotec SEView the original press release on ACCESS NewswireOriginal: Evotec SE to Announce First Quarter 2026 Results on May 6, 2026

Evotec Appoints Dr. Ingrid Müller as Chief Operating OfficerApril 15, 2026 1:50 AM
ACCESS NewswireWill play key role in strengthening cross-functional execution in support of global platform, scientific capabilities and partner delivery as well as the execution of the Horizon initiativeBrings more than 20 years of international leadership experience across operations, transformation, strategy, supply, procurement and R&D integration HAMBURG, DE / ACCESS Newswire / April 15, 2026 / Evotec SE (NASDAQ:EVO)(Frankfurt Prime Standard:EVT) today announced the appointment of Dr. Ingrid Müller as Chief Operating Officer (COO). Dr. Müller will be joining Evotec's Management Board, effective May 1, 2026. She brings to Evotec more than 20 years of international leadership experience in the life sciences industry across operations, strategy, supply, procurement and R&D integration. In her role as COO, Dr. Müller will oversee Evotec's global operations and implementation of the Horizon initiative, with a focus on quality, productivity, scalability, delivery, cost and the continued advancement of technological improvements across the business.Dr. Christian Wojczewski, Chief Executive Officer of Evotec, said:"Ingrid has built a broad international leadership profile defined by strategic perspective, operational discipline and the ability to lead cross-functional execution and transformation. She joins Evotec at a pivotal time, contributing a highly complementary combination of operational, strategic and scientific understanding, as we continue to advance our growth transformation. Her expertise in operational efficiency and delivery will play a key part in the execution of our strategy in coming years. On behalf of the whole team, I'd like to welcome Ingrid to Evotec."Most recently, Dr. Müller served as Vice President Portfolio Strategy & Execution at CureVac. Prior to that, she held senior international leadership roles at Sanofi and Fresenius Kabi, where she was instrumental in strengthening supply resilience, implementing make-or-buy strategies, supporting growth and margin expansion, and delivering annual savings and cash-flow improvements.Dr. Ingrid Müller, Evotec's designated Chief Operating Officer, added:"Evotec combines outstanding science, differentiated technology platforms and a clear commitment to making a meaningful difference. I look forward to working with colleagues across the global organization to further strengthen operational excellence, quality and delivery for our partners, and to support Evotec's next phase of focused and sustainable growth."About Evotec SEEvotec is a life science company that is pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies, we accelerate the journey from concept to cure - faster, smarter, and with greater precision. Our expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling. With flexible partnering models tailored to our customers' needs, we work with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders. Our offerings range from standalone services to fully integrated R&D programs and long-term strategic partnerships, combining scientific excellence with operational agility. Through Just - Evotec Biologics, we redefine biologics development and manufacturing to improve accessibility and affordability. With a strong portfolio of over 100 proprietary R&D assets, most of them being co-owned, we focus on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology, and immunology. Evotec's global team of more than 4,800 experts operates from sites in Europe and the U.S., offering complementary technologies and services as synergistic centers of excellence. Learn more at www.evotec.com and follow us on LinkedIn and X/Twitter @Evotec.Forward-looking statementsThis announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec's expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.Investor Relations and Media ContactDr. Sarah Fakih
EVP Head of Global Communications & Investor Relations
Sarah.Fakih@evotec.comSOURCE: Evotec SEView the original press release on ACCESS NewswireOriginal: Evotec Appoints Dr. Ingrid Müller as Chief Operating Officer

Evotec Nominates Dieter Weinand as Supervisory Board ChairmanApril 7, 2026 3:00 AM
ACCESS NewswireStrengthens Supervisory Board leadership to support Evotec's transformation, with a focus on commercial execution, strategic partnerships and profitabilityIndustry veteran brings more than 30 years of global pharmaceutical industry leadership experience across senior management, commercial, operational and strategic roles HAMBURG, DE / ACCESS Newswire / April 7, 2026 / Evotec SE (NASDAQ:EVO)(Frankfurt Prime Standard:EVT) today announced that the Supervisory Board of Evotec SE has proposed the election of Dieter Weinand, M.S. as Chairman of the Supervisory Board at the June 11, 2026, Annual General Meeting. The nomination reflects Evotec's continued commitment to strengthening commercial execution, strategic partnerships and long-term value creation.Dieter Weinand is proposed to succeed Prof. Dr. Iris Löw-Friedrich, whose term as Chairwoman of the Supervisory Board will conclude at the end of the 2026 Annual General Meeting, in line with the company's planned succession process.Dr. Christian Wojczewski, Chief Executive Officer of Evotec, said:"Dieter is an outstanding choice for Chairman as we continue to transform Evotec into a more efficient, focused and sustainably profitable company. He brings deep commercial expertise, a strong understanding of the evolving pharmaceutical landscape and extensive board and governance experience. His proven track record in leading pharmaceutical businesses, driving performance and building strategic partnerships will be instrumental as we enhance the value of our scientific platform and strengthen our collaborations with partners and customers.On behalf of the Management Board, I would like to express our sincere gratitude to Prof. Dr. Iris Löw-Friedrich for her outstanding leadership and long-standing commitment as Chairwoman of the Supervisory Board, and for the important role she has played in shaping Evotec's strategic development."Mr. Weinand currently serves on the boards of Replimune and Coya Therapeutics and as Chairman of the Board of a number of private biotech companies. He will reduce the number of his board seats in compliance with section C.5 of the German Corporate Governance Code to ensure that he can devote sufficient time and attention to his role as Chairperson of the Supervisory Board of Evotec.Mr. Weinand was previously a member of the Board of Management of Bayer AG and served as President, CEO and Chairman of the Board of Bayer Pharmaceuticals AG and has led business operations in the Asia-Pacific region, Europe, the Middle East, Africa, Latin America and the U.S. for companies, including Pfizer, Bristol Myers Squibb and Sanofi. Mr. Weinand has led the development, launch and commercialization of products in various therapeutic areas, including cardiovascular diseases, oncology, dermatology, immunology and respiratory and inflammatory diseases. He is a former board member of pharma industry associations, including PhRMA, EFPIA and IFPMA. He earned an M.S. in pharmacology and toxicology from Long Island University, New York, and a B.A. in biology from Concordia College, New York.Mr. Weinand, Evotec's nominated candidate for Chairman of the Supervisory Board, added:"I am delighted to join Evotec at such an important stage of its development. Evotec plays an integral and growing role in the pharmaceutical R&D ecosystem. Its leading capabilities in preclinical drug discovery and development combined with advanced biologics design and manufacturing position the company as a powerful partner to the biopharma industry. I look forward to working closely with the Supervisory Board and management team to support the company's strategic priorities, provide constructive oversight and help further strengthen its relationships with customers and partners."About Evotec SEEvotec is a life science company that is pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies, we accelerate the journey from concept to cure - faster, smarter, and with greater precision. Our expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling. With flexible partnering models tailored to our customers' needs, we work with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders. Our offerings range from standalone services to fully integrated R&D programs and long-term strategic partnerships, combining scientific excellence with operational agility. Through Just - Evotec Biologics, we redefine biologics development and manufacturing to improve accessibility and affordability. With a strong portfolio of over 100 proprietary R&D assets, most of them being co-owned, we focus on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology, and immunology. Evotec's global team of more than 4,800 experts operates from sites in Europe and the U.S., offering complementary technologies and services as synergistic centers of excellence. Learn more at www.evotec.com and follow us on LinkedIn and X/Twitter @Evotec.Forward-looking statementsThis announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec's expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.Investor Relations and Media ContactDr. Sarah Fakih
EVP Head of Global Communications & Investor Relations
Sarah.Fakih@evotec.comSOURCE: Evotec SEView the original press release on ACCESS NewswireOriginal: Evotec Nominates Dieter Weinand as Supervisory Board Chairman

Evotec SE to Announce Fourth Quarter and Full-Year 2025 Results on April 8, 2026April 1, 2026 5:35 AM
ACCESS NewswireHAMBURG, DE / ACCESS Newswire / April 1, 2026 / Evotec SE (NASDAQ:EVO)(Frankfurt Prime Standard:EVT) will hold a webcast and conference call to announce its financial results for the fourth quarter and full-year 2025 and provide a business update on Wednesday, April 8, 2026. The conference call will be held in English.Webcast detailsDate: Wednesday, April 8, 2026Time: 2.00 pm CEST (12.00 pm GMT, 8.00 am EDT)To join the audio webcast and to access the presentation slides, please register via this link.The on-demand version of the webcast will be available on our website: www.evotec.com.Conference call detailsTo join the conference call, please pre-register via this link. You will then receive a confirmation email with dedicated dial-in details such as telephone number, access code and PIN to access the call.A simultaneous slide presentation for participants dialing in via phone is available under this link.About Evotec SEEvotec is a life science company that is pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies, we accelerate the journey from concept to cure - faster, smarter, and with greater precision. Our expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling. With flexible partnering models tailored to our customers' needs, we work with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders. Our offerings range from standalone services to fully integrated R&D programs and long-term strategic partnerships, combining scientific excellence with operational agility. Through Just - Evotec Biologics, we redefine biologics development and manufacturing to improve accessibility and affordability. With a strong portfolio of over 100 proprietary R&D assets, most of them being co-owned, we focus on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology, and immunology. Evotec's global team of more than 4,800 experts operates from sites in Europe and the U.S., offering complementary technologies and services as synergistic centers of excellence. Learn more at www.evotec.com and follow us on LinkedIn and X/Twitter @Evotec.Forward-looking statementsThis announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec's expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.Investor Relations and Media ContactDr. Sarah Fakih
EVP Head of Global Communications & Investor Relations
Sarah.Fakih@evotec.comSOURCE: Evotec SEView the original press release on ACCESS NewswireOriginal: Evotec SE to Announce Fourth Quarter and Full-Year 2025 Results on April 8, 2026

Evotec Appoints Dr. Ashiq H. Khan as Chief Commercial OfficerApril 1, 2026 1:50 AM
ACCESS NewswireHAMBURG, DE / ACCESS Newswire / April 1, 2026 / Evotec SE (NASDAQ:EVO)(Frankfurt Prime Standard:EVT) today announced the appointment of Dr. Ashiq H. Khan as EVP Global Head, Chief Commercial Officer. Dr. Khan brings to Evotec over 15 years of international leadership experience in biotech, CRO and AI-driven platform businesses, with a distinguished track record of managing diverse transcontinental teams and closing more than $7 billion in high-value standalone, integrated, and collaboration agreements across the U.S., EU and APAC markets. In his role, Dr. Khan will spearhead the build-out of a globally integrated, fit-for-purpose commercial organization fully aligned with Evotec's scientific leadership and platform capabilities to deliver enhanced customer value and drive more robust, sustainable growth.Dr. Christian Wojczewski, Chief Executive Officer of Evotec, said:"Ashiq has demonstrated tremendous success driving growth in innovative areas like robotics, artificial intelligence and cutting-edge drug discovery platforms. His expertise is essential for executing the next stage of Evotec's transformation as a responsive drug discovery and development engine built around high-value services and capabilities. We are excited to have someone with his experience in recognizing and creating new opportunities at the helm of our commercial team."Dr. Khan most recently served as Chief Business Officer at Iktos. Prior to that, he held leadership roles at Proteros and Schrödinger. He holds a Ph.D. in Neurobiology from the University of Cologne and business degrees from the Wharton Business School and INSEAD.Dr. Ashiq H. Khan, Evotec's designated Chief Commercial Officer, added:"Evotec is uniquely positioned to advance early-stage drug discovery and development, underpinned by its industry-validated platforms, deep scientific expertise, and proven commercial models. As new technologies continue to transform the field, I am fully committed to working with Evotec's exceptional scientific, operational, and business leaders to further strengthen our capabilities and drive the next generation of breakthrough therapies."About Evotec SEEvotec is a life science company that is pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies, we accelerate the journey from concept to cure - faster, smarter, and with greater precision. Our expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling. With flexible partnering models tailored to our customers' needs, we work with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders. Our offerings range from standalone services to fully integrated R&D programs and long-term strategic partnerships, combining scientific excellence with operational agility. Through Just - Evotec Biologics, we redefine biologics development and manufacturing to improve accessibility and affordability. With a strong portfolio of over 100 proprietary R&D assets, most of them being co-owned, we focus on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology, and immunology. Evotec's global team of more than 4,800 experts operates from sites in Europe and the U.S., offering complementary technologies and services as synergistic centers of excellence. Learn more at www.evotec.com and follow us onLinkedIn and X/Twitter @Evotec.Forward-looking statementsThis announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec's expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.Investor Relations and Media ContactDr. Sarah Fakih
EVP Head of Global Communications & Investor Relations
Sarah.Fakih@evotec.comSOURCE: Evotec SEView the original press release on ACCESS NewswireOriginal: Evotec Appoints Dr. Ashiq H. Khan as Chief Commercial Officer

Just - Evotec Biologics Enters Project Agreement with BARDA to Optimize Biomanufacturing of Antibodies Against Ebola and Related VirusesMarch 23, 2026 3:10 AM
ACCESS NewswireThe program leverages Just - Evotec Biologics' advanced biomanufacturing platform to deliver high-quality, scalable, cost-efficient production through significantly higher yieldsManufacturing process development strengthens U.S. government response capabilities against hemorrhagic fever outbreaks caused by Ebola and Sudan virus HAMBURG, DE / ACCESS Newswire / March 23, 2026 / Evotec SE (NASDAQ:EVO)(Frankfurt Prime Standard:EVT) today announced its Seattle-based subsidiary and CDMO, Just - Evotec Biologics, Inc., has been selected by the Biomedical Advanced Research and Development Authority (BARDA) Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium) to advance manufacturing optimization for a monoclonal antibody cocktail targeting filovirus diseases, including Ebola virus (EBOV) and Sudan virus (SUDV).The multi-year program award, valued at up to $10 m if all options are activated, will support BARDA's efforts to strengthen national preparedness by supporting the development of cost-effective medical countermeasures that can augment the U.S. government's response capabilities with therapeutics targeting filovirus diseases. The agreement has a base period and two option periods. While two FDA approved therapeutics are currently available for Ebola Virus Disease, no approved treatments exist for infections caused by SUDV.Linda Zuckerman, PhD, EVP Global Head of Biotherapeutics at Just - Evotec Biologics commented: "In outbreak scenarios, speed, scalability and manufacturing robustness are critical. Our technology-driven approach is designed to deliver resilient, industry-leading high-yield production processes that can support rapid deployment in public health emergencies."Under the agreement, Just - Evotec Biologics will utilize its validated technology platforms to perform molecular optimization, cell line development, and manufacturing process development for two antibodies. These antibodies, originally identified in survivors of the 2014 Ebola outbreak, represent aspects of an immune response that may have protected infected individuals. Just - Evotec Biologics will apply its platform technologies to convert these discoveries into high-yield, scalable and cost-efficient manufacturing processes capable of supporting future therapeutic development and emergency deployment.This project has been funded in whole or in part with federal funds from the U.S. Department of Health and Human Services; Administration for Strategic Preparedness and Response (ASPR); Biomedical Advanced Research and Development Authority, under OT number #75A50123D00003.About BARDAThe Biomedical Advanced Research and Development Authority(BARDA) withinthe U.S Department of Health and Human Services'(HHS) Administration for Strategic Preparedness and Response (ASPR) is responsible for the advanced research, development, and procurement of medical countermeasures, for chemical, biological, radiological and nuclear (CBRN) threats, as well as pandemic influenza and emerging infectious diseases.About the Biopharmaceutical Manufacturing Preparedness ConsortiumThe Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium) supports BARDA and is comprised of industry partners across the drug and vaccine manufacturing supply chain, including manufacturers of required raw materials and consumables, developers of innovative manufacturing technologies, and suppliers of fill finish services. The consortium seeks to expand the industrial and manufacturing base for medical countermeasures to include the requisite capabilities, flexibilities, and strategies to secure needed medical supplies to prepare the United States for future health security threats. Visit biomap-consortium.org to learn more and follow @BioMaP-Consortium on LinkedIn.About Just - Evotec BiologicsJust - Evotec Biologics, wholly owned by Evotec SE, is a first-to-industry biologics platform company that leverages AI/ML technologies and world-leading molecular design, cell line development, process intensification and continuous manufacturing strategies to advance biotherapeutics from discovery through clinical stages to commercial launch. The Just - Evotec Biologics team combines deep industry experience in the fields of data, protein, process, and manufacturing sciences including automation with highly integrated and flexible capabilities to break through the scientific and economic barriers associated with the development of protein therapeutics. Our focus is to accelerate and expand access to biotherapeutics through scientific and technological innovation for our proprietary projects and on behalf of our partners. Learn more at www.just-evotecbiologics.com.About Evotec SEEvotec is a life science company that is pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies, we accelerate the journey from concept to cure - faster, smarter, and with greater precision. Our expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling. With flexible partnering models tailored to our customers' needs, we work with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders. Our offerings range from standalone services to fully integrated R&D programs and long-term strategic partnerships, combining scientific excellence with operational agility. Through Just - Evotec Biologics, we redefine biologics development and manufacturing to improve accessibility and affordability. With a strong portfolio of over 100 proprietary R&D assets, most of them being co-owned, we focus on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology, and immunology. Evotec's global team of more than 4,800 experts operates from sites in Europe and the U.S., offering complementary technologies and services as synergistic centers of excellence. Learn more at www.evotec.com and follow us on LinkedIn and X/Twitter @Evotec.Forward-looking statementsThis announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec's expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.Investor Relations and Media Contact
Dr. Sarah Fakih
EVP Head of Global Communications & Investor Relations
Sarah.Fakih@evotec.comSOURCE: Evotec SEView the original press release on ACCESS NewswireOriginal: Just - Evotec Biologics Enters Project Agreement with BARDA to Optimize Biomanufacturing of Antibodies Against Ebola and Related Viruses

Evotec Receives $10 M Milestone from Bristol Myers Squibb Protein Degradation Collaboration for Clinical Study InitiationMarch 19, 2026 2:50 AM
ACCESS NewswireDosing of first patient initiates Phase 1 clinical evaluation of BMS-986506 for the treatment of advanced clear cell renal cell carcinoma, the most common form of kidney cancerTransformative moment in strategic protein degradation collaboration with Bristol Myers Squibb (BMS) aiming to establish new treatment paradigm in advanced clear cell renal cell carcinomaStudy start highlights transition into the clinic for Evotec-BMS oncology platform and reflects robust pipeline of ‘molecular glues' being advanced as treatment options for different cancer typesValidates Evotec's high-performance multi-omics screening and AI-supported data analytics and drug design capabilities HAMBURG, DE / ACCESS Newswire / March 19, 2026 / Evotec SE (NASDAQ:EVO)(Frankfurt Prime Standard:EVT) today announced that its partner Bristol Myers Squibb (BMS) has initiated a Phase 1 clinical study evaluating CELMoD agent BMS-986506, a cereblon E3 ligase modulator, in clear cell renal cell carcinoma, the most common form of kidney cancer.Initiation of the first-in-human study represents a significant advancement in the strategic protein degradation collaboration, bringing into the clinic a novel CELMoD or ‘molecular glue' candidate jointly generated through Evotec's powerful and fully integrated drug discovery platform. This platform combines high-performance multi-omics screening with AI-enabled data analytics and drug design capabilities, selectively prompting cancer cells to eliminate disease-driving proteins. As a result of this clinical progression, Evotec will receive a milestone payment of $10 million.Dr. Cord Dohrmann, Chief Scientific Officer of Evotec said:"In this unique collaboration, we follow a systematic approach to discovering molecular glues with tremendous therapeutic potential. Together with Bristol Myers Squibb, and building on Evotec's PanOmics and PanHunter platforms, we have identified a broad portfolio of high-potential molecular glue drug candidates that are now beginning to enter clinical development. The initiation of this Phase 1 clinical trial marks the first clinical milestone in the strategic protein degradation partnership with BMS. Molecular glues have the potential to address significant unmet medical need not only in oncology, but far beyond, by targeting previously undruggable, disease-causing proteins and thereby aiming to reshape future standards of care."BMS-986506 was developed under the strategic protein degradation partnership between Evotec and Bristol Myers Squibb. The collaboration combines PanOmics, Evotec's high-performance multi-omics screening platform as well as PanHunter, Evotec's AI-supported data omics analytics platform with BMS's industry-leading library of CELMoDs™ agents. Initiated in 2018 and expanded in 2022, the collaboration is continuing to deliver on its goal to identify novel molecular glue degraders for high-value targets in the field of oncology and beyond.About Molecular Glue DegradersConventional small molecule therapeutics work via a drug-induced interference with a protein activity. This limitation to agonistic or antagonistic functions renders about 90% of proteins "undruggable". Conventional small molecules only work while they are actively binding to the receptor, which typically requires a treatment regimen consisting of one or even several carefully dosed medications every day.Molecular glue degraders are compounds that induce interactions between an E3 ubiquitin ligase and a molecular target. The induced interaction results in ubiquitination and degradation of the recruited protein. This event-driven mechanism of action significantly expands the range of the druggable proteome. The molecular glue is not degraded in the process and can trigger the degradation process many times over, thus leading to longer-lasting therapeutic effects.About Evotec's Strategic Collaboration with Bristol Myers Squibb in Molecular GluesIn 2018, Evotec entered a long-term strategic drug discovery and development collaboration in the field of molecular glues with Celgene, now Bristol Myers Squibb. BMS is a leader in this field based on its unique library of CELMoDs™ agents. The collaboration aims to discover and develop a leading pipeline of molecular glue degraders for a range of therapeutic indications leveraging all of Evotec's proprietary PanOmics and PanHunter platforms as well as AI/ML-based drug discovery and development capabilities.Evotec applies high-end proteomics and transcriptomics at industrial scale to profile and select promising drug candidates based on comprehensive cell biological profiles. Evotec's leading PanOmics screening capabilities are delivering unmatched throughput. The selection of the most promising candidates for drug development is facilitated by Evotec's PanOmics data analysis platform PanHunter. It supports the integration and analysis of these data sets and thereby enables the selection of the most promising CELMoDs™ for further progression into lead optimization.About Evotec SEEvotec is a life science company that is pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies, we accelerate the journey from concept to cure - faster, smarter, and with greater precision. Our expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling. With flexible partnering models tailored to our customers' needs, we work with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders. Our offerings range from standalone services to fully integrated R&D programs and long-term strategic partnerships, combining scientific excellence with operational agility. Through Just - Evotec Biologics, we redefine biologics development and manufacturing to improve accessibility and affordability. With a strong portfolio of over 100 proprietary R&D assets, most of them being co-owned, we focus on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology, and immunology. Evotec's global team of more than 4,800 experts operates from sites in Europe and the U.S., offering complementary technologies and services as synergistic centers of excellence. Learn more at www.evotec.com and follow us on LinkedIn and X/Twitter @Evotec.Forward-looking statementsThis announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec's expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.Investor Relations and Media Contact
Dr. Sarah Fakih
EVP Head of Global Communications & Investor Relations
Sarah.Fakih@evotec.comSOURCE: Evotec SEView the original press release on ACCESS NewswireOriginal: Evotec Receives $10 M Milestone from Bristol Myers Squibb Protein Degradation Collaboration for Clinical Study Initiation

Evotec jumps 8% after Berenberg starts coverage with “buy” on partner upsideFebruary 3, 2026 11:18 AM
IH Market News
Shares in Evotec SE (NASDAQ:EVO) climbed 8% after Berenberg initiated coverage of the German biotech group with a buy recommendation, arguing that the market is undervaluing the company’s strategic partnerships and core discovery platform.Berenberg assigned a €10 price target, well above Evotec’s previous close of €5.90 on Xetra.According to the brokerage, Evotec’s share-price weakness reflects cyclical pressures in biotech financing and short-term execution challenges rather than any fundamental deterioration in the business. Berenberg said recent investor concerns have incorrectly treated these headwinds as structural.Evotec operates as a contract research organization, offering drug discovery, preclinical development and biologics manufacturing services to pharmaceutical companies, biotech groups and academic partners. The company generated €781 million in revenue in 2023 and recorded negative EBITDA of €41 million that year, based on figures cited by Berenberg.The bank said its initiation is grounded in the belief that the biotech funding slowdown that weighed on Evotec in 2024 and 2025 has been misinterpreted by the market. Funding levels have now stabilized around pre-pandemic norms, which historically supported consistent demand for outsourced research services.“Evotec sits at the intersection of rising R&D outsourcing demand and a growing need for capital-efficient drug discovery innovation,” analyst Christian Ehmann wrote. He added that the company’s capabilities and long-term agreements “remain intact” despite near-term softness in early-stage discovery activity.A key pillar of Berenberg’s investment thesis is Evotec’s collaboration with Sandoz, which includes development work on 10 biosimilars using Evotec’s biologics platform. In July 2025, Evotec agreed to transfer its Toulouse biologics site, J.POD 2, to Sandoz, moving the partnership toward an asset-light model featuring upfront payments, development fees, milestones and royalties.Berenberg said the revised structure strengthens Evotec’s liquidity position and lowers execution risk, while still allowing the company to participate in the long-term upside of Sandoz’s biosimilar pipeline. The brokerage expects Evotec to earn low-single-digit royalties on net sales once products reach the market, alongside development and milestone payments between 2026 and 2030.Ehmann noted that the new structure accelerates cash inflows and eliminates a loss-making ramp-up phase, marking a return to Evotec’s traditional capital-light operating approach.The bank also highlighted Evotec’s exposure to large pharmaceutical customers under long-term contracts, including Bristol Myers Squibb and Janssen, as a stabilizing influence. Berenberg said this client mix, together with cost reductions and management changes introduced in 2024 and 2025, should gradually improve earnings quality.Evotec reported an EBITDA margin of -5.2% in 2024, which Berenberg expects to turn positive in 2025 and improve to 10.3% in 2026. Revenue is forecast to decline to €751 million in 2026 from €797 million in 2024, before rebounding to €817 million in 2027.At current valuation levels, Berenberg argued that the market assigns little value to Evotec’s biologics capabilities and long-duration partnerships. “The downside is increasingly reflected in the share price,” Ehmann said, adding that a normalization in demand and better earnings visibility could be enough to trigger a re-rating.Evotec stock price

Original: Evotec jumps 8% after Berenberg starts coverage with “buy” on partner upside

Evotec was an early adopter of incoroporating AlphFold

AlphaFold has fundamentally changed medical research by providing a powerful and rapid tool for predicting protein structures, accelerating drug discovery, and deepening the understanding of disease mechanisms

The development of AlphaFold, particularly its second and third versions, has been described as a revolution comparable in importance to the advent of genomics.

Not getting a lot of press but the latest versions of AlphaFold are about to change medicine. Many are now incorporating it but this small player offers the most bang for the buck if they get it right.

The potential that brought a $11/share buyout offer
Evotec is a leader in targeted protein degradation (TPD), a strategy that addresses the downstream effects of misfolding by removing disease-causing proteins. This approach is central to its partnerships with companies like Bristol Myers Squibb.

EVO
Evotec SE
3.27
0.10 (3.15%)
Volume: 65,549
Day Range: 3.20 - 3.275
Last Trade Time: 1:22:46 PM EDT

https://www.stockscores.com/charts/charts/?ticker=EVO

$EVO

http://www.stockcharts.com/c-sc/sc?s=EVO&p=W&b=5&g=0&i=p86431144783&r=1726846497545

EVO
Evotec SE
3.46
0.04 (1.17%)
Volume: 178,752
Day Range: 3.30 - 3.45
Last Trade Time: 5:15:50 PM EDT

EVO
Evotec SE
4.7699
-0.0101 (-0.21%)
Volume: 13,825
Day Range: 4.75 - 4.91
Last Trade Time: 2:11:00 PM EDT

EVO
Evotec SE
4.51
-0.07 (-1.53%)
Volume: 18,067
Day Range: 4.50 - 4.58
Last Trade Time: 12:09:35 PM EDT

EVO under $10

EVO 10Q due 3/25
Next day settlement begins 5/28 per SEC mandate

EVO
Evotec SE
7.32
0.18 (2.52%)
Volume: 63,724
Day Range: 7.12 - 7.32
Last Trade Time: 5:34:38 PM EDT
Delayed by 15 minutes

Like it yes I do.

https://www.otcmarkets.com/stock/EVO

https://www.otcmarkets.com/stock/EVO

https://www.otcmarkets.com/stock/EVO

O.K. HOW LIKE $EVO ?????

Hi mick can you make this post sticky on ABQQ board thank you https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173150762

[-chart]www.stockscores.com/chart.asp?TickerSymbol=EVO&TimeRange=950&Interval=d&Volume=1&ChartType=CandleStick&Stockscores=1&ChartWidth=1100&ChartHeight=480&avgType1=&movAvg1=&avgType2=&movAvg2=&candles=redgreen[/chart]

[-chart]www.stockscores.com/chart.asp?TickerSymbol=EVO&TimeRange=950&Interval=d&Volume=1&ChartType=CandleStick&Stockscores=1&ChartWidth=1100&ChartHeight=480&avgType1=&movAvg1=&avgType2=&movAvg2=&candles=redgreen[/chart]

[-chart]www.stockscores.com/chart.asp?TickerSymbol=EVO&TimeRange=950&Interval=d&Volume=1&ChartType=CandleStick&Stockscores=1&ChartWidth=1100&ChartHeight=480&avgType1=&movAvg1=&avgType2=&movAvg2=&candles=redgreen[/chart]

thank you shelly, it reads now

https://www.barchart.com/stocks/quotes/EVO

https://www.barchart.com/stocks/quotes/EVO

https://www.otcmarkets.com/stock/EVO/security

COULD BE ONE TO WATCH, FOLLOW OR TO CHART $EVO